23073-51-0

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-1-ethylbenzoimidazole is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs with improved therapeutic properties. Its unique structure allows for the creation of diverse chemical entities with potential applications in treating various diseases and conditions.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-Bromo-1-ethylbenzoimidazole is utilized as a key intermediate in the synthesis of pesticides and other agrochemicals. Its incorporation into these compounds can enhance their effectiveness in controlling pests and diseases, thereby improving crop yields and food security.
Used in Organic Synthesis:
5-Bromo-1-ethylbenzoimidazole serves as a reagent in organic synthesis, particularly for the formation of heterocyclic compounds. Its presence in these reactions can facilitate the synthesis of complex organic molecules with potential applications in various fields, including materials science, pharmaceuticals, and agrochemicals.
Used in Medicinal Chemistry Research:
Due to its potential biological activities, 5-Bromo-1-ethylbenzoimidazole is of interest for medicinal chemistry research. Scientists are exploring its properties and interactions with biological targets to identify new therapeutic agents and drug candidates for the treatment of various diseases and conditions.
Safety and Handling:
It is important to handle 5-Bromo-1-ethylbenzoimidazole with care, as it may pose hazards if not used and stored properly. Proper safety measures, such as wearing protective clothing, using appropriate containment, and following established safety protocols, should be implemented to minimize risks associated with 5-Bromo-1-ethylbenzoimidazole.

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 149-73-5 trimethyl orthoformate 
• 56136-82-4 (4-bromo-2-nitrophenyl)ethylamine 
• 74-96-4 ethyl bromide 
• 4887-88-1 5-bromo-1H-benzo[d]imidazole 
• 875-51-4 4-Bromo-2-nitroaniline 

Relevant academic research and scientific papers

INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Hetero- A nd Homobimetallic Complexes Bridged by a Bis(NHC) Ligand: Synthesis via Selective Sequential Metalation and Catalytic Applications in Tandem Organic Transformations

A (bis)azolium salt [L1-H2]Br2 (5), synthesized following multistep procedures, was realized to be a suitable platform for accessing the bis(NHC) ligand supported heterobimetallic IrIII-M (M = PdII/AuI) complexes via a sequential metalation strategy for their potential catalytic applications in one-pot tandem organic transformations. First, the reaction of 5 with 0.5 equiv of [Ir(Cp-)Cl2]2 selectively yielded a monometallic IrIII complex 6, which was further metalated using Pd(OAc)2/NaOAc to afford the heterobimetallic IrIII-PdII complex 7. On the other hand, complex 6 was reacted with Ag2O, followed by transmetalation with [Au(SMe2)Cl] in a one-pot manner, to yield the IrIII-AuI complex 8. Further, the related homobimetallic IrIII and PdII complexes 9 and 10, respectively, have also been synthesized directly from [L1-H2]Br2. All the homo/heterobimetallic complexes have been well-characterized by multinuclear NMR spectroscopy, ESI-mass spectrometry, and via single-crystal X-ray diffraction studies of the complexes 7, 8, and 10. The heterobimetallic IrIII-PdII complex 7 has been tested as a catalyst for three one-pot tandem catalytic reactions: (a) Suzuki-Miyaura coupling and transfer hydrogenation of ketones, (b) hydrodefluorination and transfer hydrogenation of ketones, and (c) hydrodehalogenation and transfer hydrogenation of imines. Importantly, the catalytic activity of heterobimetallic complex 7 in the above-mentioned reactions was found to be better than the mixture of their corresponding homobimetallic counterparts 9 and 10, keeping the concentration of the metal centers constant. These observations affirm some sort of cooperativity between the two metal centers (Ir and Pd) connected via a single ligand frame in 7 when catalytic activity is concerned, which thus constitutes a superior catalytic system than that of the cases where two separate metal complexes (hence, the two metal centers are not connected by a single ligand framework) are used.